– USA, MA – Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics, today announced the elections of Paul Mango and Tim Wicks to its Board of Directors at the 2022 AGM on June 14, 2022, and the appointment of Shiva Rajaraman as a member of the Board, which now includes seven directors, of whom six are independent.
“We are pleased to welcome Paul, Shiva and Tim to our Board as we work to improve healthcare by pioneering software as a mainstream medical treatment. They bring a breadth and depth of experience across healthcare and technology, and we expect that they will bring their own unique insights to a Board that is comprised of a diverse set of experiences in these industries as we continue to execute our strategy and enhance value for all Pear shareholders,” said CEO, Dr. Corey McCann.
Paul Mango will join the Audit Committee and the Nominating and Corporate Governance Committee; Shiva Rajaraman will join the Compensation Committee and the Nominating and Corporate Governance Committee, and Tim Wicks will join the Audit Committee and Compensation Committee.
About Paul Mango
Mr. Mango brings to the board experience in both the healthcare industry and government. He has previously served as Deputy Chief of Staff for Policy at the U.S. Department of Health and Human Services, as Chief Principal Deputy Administrator and Chief of Staff at the Center for Medicare and Medicaid Services, and as a Senior Partner at McKinsey & Company.
He currently serves on the Board of Directors of two private companies, Cogitativo, Inc. and Healthmine, Inc.
He earned a Bachelor of Science in Engineering from the United States Military Academy at West Point and an MBA from Harvard University.
About Shiva Rajaraman
Mr. Rajaraman brings to the board deep experience in building out exceptional technology products. He is currently the VP of Product at OpenSea. Before that, he served as VP of Commerce at Meta, formerly known as Facebook, and has worked for a variety of other technology companies, including Google, Spotify, and WeWork.
He earned a bachelor’s degree from the University of California, Berkeley, and an MBA from the Wharton School of Business at the University of Pennsylvania.
About Tim Wicks
Mr. Wicks brings to the board deep healthcare industry experience, most recently with UnitedHealth Group until his retirement in 2021. During his nearly 20 years with UNH, he served as both an EVP and CFO at Optum, Inc. and as the EVP of Supply Chain and CEO and President of OptumRx, Inc. Previously, Mr. Wicks has held executive positions at Dell Technologies, Bain & Company, Northwest Airlines, and Yellow Corp, among others. Mr. Wicks has previously served on the board and as a member of the Finance and Audit Committee of two public companies–Precision Castparts Corp and Aerojet Rocketdyne.
Mr. Wicks earned a Bachelor of Arts in Economics from the University of Chicago and an MBA from Harvard University.
About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics, Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics. Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive a Breakthrough Designation. Pear’s third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.
For more information: https://peartherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
